Clinical trial
A Phase I First in Human, Randomized, Double-blind, Placebo- Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability and Pharmacokinetics of LPX-TI641 After Single and Multiple Oral Doses.
NCT05853835 is registered in ClinicalTrials.gov with LAPIX Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I First in Human, Randomized, Double-blind, Placebo- Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability and Pharmacokinetics of LPX-TI641 After Single and Multiple Oral Doses.
- Lead sponsor
- LAPIX Therapeutics Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 30, 2023
- Completion date
- November 1, 2024
- Enrollment
- 72 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.